UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MAP3K11/GDF15 axis is a critical driver of cancer cachexia

Journal of cachexia, sarcopenia and muscle, 2016-09, Vol.7 (4), p.467-482

2016

Volltextzugriff (PDF)

Drug-Sensitive FGFR2 Mutations in Endometrial Carcinoma

Proceedings of the National Academy of Sciences - PNAS, 2008-06, Vol.105 (25), p.8713-8717

2008

Volltextzugriff (PDF)

Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss

Oncology letters, 2016-11, Vol.12 (5), p.4219-4223

2016

Volltextzugriff (PDF)

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients

Journal of cachexia, sarcopenia and muscle, 2015-12, Vol.6 (4), p.317-324

2015

Volltextzugriff (PDF)

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Nature genetics, 2010-08, Vol.42 (8), p.715-721

2010

Volltextzugriff (PDF)

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models

Clinical cancer research, 2015-03, Vol.21 (5), p.1106-1114

2015

Volltextzugriff (PDF)

Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1153-1153

2015

Volltextzugriff (PDF)

23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity

Molecular cancer therapeutics, 2015-08, Vol.14 (8), p.1858-1867

2015

Volltextzugriff (PDF)

SP696ASSOCIATION OF THE NOVEL CACHEXIA MARKER “GROWTH DIFFERENTIATION FACTOR 15” (GDF15) WITH MORTALITY IN HEMODIALYSIS PATIENTS

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii609-iii609

2015

Volltextzugriff (PDF)

Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.361-361

2013

Volltextzugriff (PDF)

Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3504-3504

2013

Volltextzugriff (PDF)

Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4650-4650

2013

Volltextzugriff (PDF)

Abstract 2000: Biological function annotation of microarray data using correlated gene indices

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2000-2000

2010

Volltextzugriff (PDF)

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients: GDF15 in cancer-related weight loss

Journal of cachexia, sarcopenia and muscle, 2015-12, Vol.6 (4), p.317-324

2015

Volltextzugriff (PDF)

Population-based engineered tumor models as a platform for biomarker discovery in cancer

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.B10-B10

2010

Volltextzugriff (PDF)

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5063-5063

2011

Volltextzugriff (PDF)

Abstract B18: Variation in response to VEGFR inhibitor tivozanib in a unique population-based tumor model enables the development of a multigene response biomarker

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B18-B18

2009

Volltextzugriff (PDF)

Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3267-3267

2010

Volltextzugriff (PDF)

Amendment Free, Mechanically Enhanced Biodrying & Composting of Dewatered Undigested Sewage Sludge

Proceedings of the Water Environment Federation, 2009-01, Vol.2009 (3), p.914-943

2009

Volltextzugriff (PDF)

AGITATED BAY COMPOSTING IN ARDMORE, OKLAHOMA

BioCycle, 2007-07, Vol.48 (7), p.50

2007

Volltextzugriff (PDF)

Comparing positive and negative aeration at in-vessel facility

BioCycle, 2005-06, Vol.46 (6), p.36-41

2005

Volltextzugriff (PDF)

Metabotropic glutamate receptors as drug targets: what's new?

Current opinion in pharmacology, 2015-02, Vol.20, p.89-94

2015

Volltextzugriff (PDF)

No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19

European spine journal, 2021-06, Vol.30 (6), p.1699-1707

2021

Volltextzugriff (PDF)

Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status

Expert opinion on therapeutic targets, 2019-04, Vol.23 (4), p.341-351

2019

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(115)

Publikationsform

Sprache

Englisch
(124)
Japanisch
(18)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Epilepsia
(9)
Cancer Research
(6)
Oncotarget
(4)
Cell Cycle
(3)
Journal Of Cachexia, Sarcopenia And Muscle
(3)
Plos One
(3)
Biocycle
(2)
Brain Research
(2)
Cardiovascular Pathology
(2)
Cell Cycle/cell Cycle
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

MAP3K11/GDF15 axis is a critical driver of cancer cachexia

Drug-Sensitive FGFR2 Mutations in Endometrial Carcinoma

Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models

Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody

23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity

SP696ASSOCIATION OF THE NOVEL CACHEXIA MARKER “GROWTH DIFFERENTIATION FACTOR 15” (GDF15) WITH MORTALITY IN HEMODIALYSIS PATIENTS

Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride

Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients

Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia

Abstract 2000: Biological function annotation of microarray data using correlated gene indices

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients: GDF15 in cancer-related weight loss

Population-based engineered tumor models as a platform for biomarker discovery in cancer

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Abstract B18: Variation in response to VEGFR inhibitor tivozanib in a unique population-based tumor model enables the development of a multigene response biomarker

Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery

Amendment Free, Mechanically Enhanced Biodrying & Composting of Dewatered Undigested Sewage Sludge

AGITATED BAY COMPOSTING IN ARDMORE, OKLAHOMA

Comparing positive and negative aeration at in-vessel facility

Metabotropic glutamate receptors as drug targets: what's new?

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19

Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status

Suchergebnisse filtern